Business Description
Viridian Therapeutics Inc
NAICS : 325199
SIC : 2834
ISIN : US92790C1045
Description
Financial Strength
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 27.26 | |||||
Equity-to-Asset | 0.9 | |||||
Debt-to-Equity | 0.04 | |||||
Debt-to-EBITDA | -0.09 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 17.57 | |||||
Beneish M-Score | -5.98 | |||||
WACC vs ROIC |
Growth Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -71.3 | |||||
3-Year EBITDA Growth Rate | 44.6 | |||||
3-Year EPS without NRI Growth Rate | 22.7 | |||||
3-Year FCF Growth Rate | 21 | |||||
Future 3-5Y EPS without NRI Growth Rate | 7.7 | |||||
Future 3-5Y Total Revenue Growth Rate | 329.87 |
Momentum Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 59.36 | |||||
9-Day RSI | 58.93 | |||||
14-Day RSI | 60.09 | |||||
6-1 Month Momentum % | 37.46 | |||||
12-1 Month Momentum % | 75.9 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 15.82 | |||||
Quick Ratio | 15.82 | |||||
Cash Ratio | 15.54 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -133.7 | |||||
Shareholder Yield % | -10.91 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -87078.47 | |||||
Net Margin % | -79185.76 | |||||
FCF Margin % | -58581.94 | |||||
ROE % | -52.95 | |||||
ROA % | -47.78 | |||||
ROIC % | -1788.9 | |||||
ROC (Joel Greenblatt) % | -6514.28 | |||||
ROCE % | -50.18 |
GF Value Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 4852 | |||||
PB Ratio | 4.7 | |||||
Price-to-Tangible-Book | 4.82 | |||||
EV-to-EBIT | -6.5 | |||||
EV-to-EBITDA | -6.52 | |||||
EV-to-Revenue | 5089.67 | |||||
EV-to-Forward-Revenue | 4707.56 | |||||
EV-to-FCF | -8.69 | |||||
Price-to-Median-PS-Value | 483.2 | |||||
Price-to-Net-Current-Asset-Value | 4.88 | |||||
Price-to-Net-Cash | 3.09 | |||||
Earnings Yield (Greenblatt) % | -15.38 | |||||
FCF Yield % | -9.11 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Viridian Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 0.288 | ||
EPS (TTM) ($) | -4.25 | ||
Beta | 2.16 | ||
Volatility % | 87.19 | ||
14-Day RSI | 60.09 | ||
14-Day ATR ($) | 1.263737 | ||
20-Day SMA ($) | 23.127385 | ||
12-1 Month Momentum % | 75.9 | ||
52-Week Range ($) | 10.98 - 24.78 | ||
Shares Outstanding (Mil) | 76.36 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Viridian Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Viridian Therapeutics Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Viridian Therapeutics Inc Frequently Asked Questions
What is Viridian Therapeutics Inc(LTS:0K1R)'s stock price today?
When is next earnings date of Viridian Therapeutics Inc(LTS:0K1R)?
Does Viridian Therapeutics Inc(LTS:0K1R) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |